Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.


Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes

January 19th 2021

These results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population (Frontiers in Endocrinology)

Categories: Medication, News
Tags: COVID-19, metformin

Categories: Medication
Tags: COVID-19, metformin

ABCD and ABHI Position on Insulin Pumps

January 19th 2021

ABCD and ABHI have released a joint position statement “Supporting Management of People with diabetes using Out-of-Warranty Pumps while Ensuring Appropriate Patient Choice”

Categories: News, Treatment
Tags: insulin pumps

Categories: Treatment
Tags: insulin pumps

A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial

January 19th 2021

Hyperglycaemia was reduced without increasing hypoglycaemia in adolescents and young adults with type 1 diabetes using the investigational advanced hybrid closed-loop system compared with the commercially available MiniMed 670G system (The Lancet)

Categories: News, Treatment
Tags: insulin pumps, pumps, Type 1 Diabetes

Categories: Treatment
Tags: insulin pumps, pumps, Type 1 Diabetes

National Diabetes Audit, Diabetes Prevention Programme (DPP), Quarterly Data Release, 1st January – 30th September 2020

January 14th 2021

The NHS Diabetes Prevention Programme (DPP) is a joint commitment from NHS England, Public Health England (PHE) and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia

Categories: Audits, News
Tags: NHS

Categories: Audits
Tags: NHS

Global Trials Summit

January 14th 2021

Please join us for a series of vibrant and thought-provoking presentations by leaders in these fields who will discuss the results of recent pivotal trials in these areas. Live online discussions focusing on implementation of novel efficacious therapies will challenge clinicians as to how to adapt their daily practice.

Categories: Education, News
Tags: trials

Categories: Education
Tags: trials

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

January 14th 2021

In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo (NEJM)

Categories: Cardiovascular, Medication, News
Tags: sotagliflozin

Categories: Cardiovascular, Medication
Tags: sotagliflozin

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

January 13th 2021

In patients with type 2 diabetes, SGLT-2 inhibitors and GLP-1 receptor agonists reduced cardiovascular and renal outcomes, with notable differences in benefits and harms (BMJ)

Categories: Medication
Tags: DPP4i, SGLT2 inhibitors

SGLT2 inhibitors in type 2 diabetic patients with renal function impairment slows the annual renal function decline, in a real clinical practice

January 12th 2021

SGLT2is administration slows the decline observed in the annual renal function in T2DM patients with eGFR of < 60 ml/min/1.73m2, in clinical practice (Journal of Diabetes Investigation)

Categories: Nephropathy, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Nephropathy
Tags: SGLT2 inhibitors, Type 2 Diabetes

Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

January 12th 2021

This review summarizes work in the area of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i (Cardiovascular Diabetology)

Categories: Cardiovascular, Nephropathy, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Nephropathy
Tags: SGLT2 inhibitors, Type 2 Diabetes

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)

January 11th 2021

In propensity score-matched cohorts, GLP-1 RAs demonstrated significant benefits for both glycemic control and weight management over additional OAD(s) or insulin, respectively, indicating that they may represent the optimal choice at these points in the treatment pathway (BMJ Open, Diabetes Research & Care)

Categories: Medication, News
Tags: GLP1, Type 2 Diabetes

Categories: Medication
Tags: GLP1, Type 2 Diabetes

Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses

January 11th 2021

Younger, rather than older, age at diabetes diagnosis was associated with higher risk of mortality and vascular disease. Early and sustained interventions to delay type 2 diabetes onset and improve blood glucose levels and cardiovascular risk profiles of those already diagnosed are essential to reduce morbidity and mortality (Diabetologia)

Categories: News, Pathology
Tags: Type 2 Diabetes

Categories: Pathology
Tags: Type 2 Diabetes

The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review

January 11th 2021

There is a higher than expected prevalence of CAN in prediabetes. Early detection of CAN in prediabetes through population screening needs careful consideration in view of the excess morbidity and mortality risk associated with this condition (Diabetologia)

Categories: Cardiovascular, News
Tags: prediabetes

Categories: Cardiovascular
Tags: prediabetes

Sodium‐glucose cotransporter 2 inhibitor‐induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease

January 8th 2021

The degree of BP reduction after SGLT2 inhibitor treatment influenced renal composite outcomes in Japanese T2DM patients with CKD, confirming the importance of blood pressure management in T2DM patients with CKD, even when they are under SGLT2 inhibitor treatment (Journal of Diabetes Investigation)

Categories: Nephropathy
Tags: CKD, SGLT2 inhibitors, Type 2 Diabetes

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

January 7th 2021

SGLT2 inhibitors should be used when possible by people with T2DM to reduce risks for CKD and CVD in alignment with the clinical trial entry criteria (Diabetes)

Categories: Cardiovascular, News
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular
Tags: SGLT2 inhibitors, Type 2 Diabetes

Insulin-Stimulated Muscle Glucose Uptake and Insulin Signaling in Lean and Obese Humans

January 6th 2021

We suggest that reduced muscle glucose uptake in obesity is not due to defects in the insulin signaling pathway at the level of Akt/AS160, which suggests there remain significnt gaps in our knowledge of muscle insulin resistance in obesity. Our data imply that models of acute lipotoxicity don’t replicate the pathophysiology of obesity (Journal of Clinical Endocrinology & Metabolism)

Categories: News, Obesity
Tags: glucose uptake, insulin

Categories: Obesity
Tags: glucose uptake, insulin

Why diabetes outpatient clinics should not close during pandemic crises

January 5th 2021

We argue that healthcare services for people with chronic diseases, like diabetes outpatient clinics, should not shutdown totally or partially during pandemic crises, and keep serving fragile patients who are less resilient to these unprecedented stressful conditions (Journal of Endocrinological Investigation)

Categories: Management, News
Tags: OPD clinics

Categories: Management
Tags: OPD clinics

Impact of blinded retrospective continuous glucose monitoring on clinical decision making and glycemic control in persons with type 2 diabetes on insulin therapy

January 5th 2021

In persons with type 2 diabetes and poor metabolic control, specific data from blinded rCGM informed therapeutic changes and referral to targeted education consultations on nutrition and insulin administration technique (Nutrition, Metabolism & Cardiovascular Diseases)

Categories: News, Treatment
Tags: CGM, Type 2 Diabetes

Categories: Treatment
Tags: CGM, Type 2 Diabetes

Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland

January 4th 2021

Overall risks of fatal or critical care unit-treated COVID-19 were substantially elevated in those with type 1 and type 2 diabetes compared with the background population. The risk of fatal or critical care unit-treated COVID-19, and therefore the need for special protective measures, varies widely among those with diabetes but can be predicted reasonably well using previous clinical history (The Lancet Diabetes & Endocrinology)

Categories: News, Pathology
Tags: COVID-19, Type 1 Diabetes, Type 2 Diabetes

Categories: Pathology
Tags: COVID-19, Type 1 Diabetes, Type 2 Diabetes

Genomic risk score provides predictive performance for type 2 diabetes in the UK biobank

January 4th 2021

The metaGRS significantly improves T2D prediction ability (Acta Diabetologica)

Categories: Genetics, News
Tags: Type 2 Diabetes

Categories: Genetics
Tags: Type 2 Diabetes

Effect of remote management on comprehensive management of diabetes mellitus during the COVID-19 epidemic

January 3rd 2021

During the COVID-19 epidemic, diabetes treatment has been facing new challenges, and the traditional treatment mode is limited. Remote management can increase TIR without increasing the risk of hypoglycemia. Remote management can prevent weight gain and improve patients’ self-management and compliance during the COVID-19 epidemic (Primary Care Diabetes)

Categories: Management, News
Tags: COVID-19, remote management

Categories: Management
Tags: COVID-19, remote management
  • 1
  • 2
  • 3
  • …
  • 209
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

Sanofi DiabetesNovo NordiskAstraZenecaNapp Diabetes

Silver Sponsors

Abbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)Amgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

News Archive

calendar-iconNews Archive ››

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 elderly Empagliflozin exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis lada liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Recent Book and Product Reviews

  • Oxford Handbook of Emergency Medicine
  • Handbook of Obstetric Medicine
  • Ferri’s Clinical Advisor 2021
  • Oxford Case Histories in Infectious Diseases and Microbiology

Recent Diabetes Updates

  • National Diabetes Audit.
  • Funding bids
  • Publication of Studies During 2016 – Type 2 Diabetes
  • “Attitudes to obesity” findings from the 2015 survey

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com


Website by Wired up Wales

Copyright © 2021 Glycosmedia Partnership